ICBC Berlin: A Snapshot of the Industry

Market Development with Momentum 

A range of topics came up across the panels, including price developments in the flower market over recent months and the proposed changes to statutory health insurance reimbursement for medical cannabis. What stood out was how nuanced and increasingly strategic the discussion has become. Falling prices are not seen only as a challenge, but also as a sign of a maturing market in which viable business models can still succeed. The key now will be to focus on stability, quality and a broader product portfolio across different price segments. 

At the same time, the debate around statutory health insurance reimbursement made clear how important reliable political framework conditions remain for the market’s future development. The fact that medical cannabis has been reimbursable since 2017 was a major catalyst both for patient access and for the development of the market as it exists today. That makes it all the more important to continue on this path and ensure that patients retain access to the forms of therapy that best meet their needs. 

What’s Next for the Medical Cannabis Reform? 

Another key topic at ICBC was whether the MedCan reform presented last summer is still realistic in its original form. The prevailing view on the panels was that it probably is not. Many discussions suggested that the political assessment has shifted in the meantime: mail order supply and digital prescribing models are increasingly no longer seen as the core problem, but rather as part of a modern healthcare framework. As a result, many in the industry expect that if the reform is pursued at all, it will look quite different from the version outlined last year. 

Case Law Instead of Additional Special Regulation 

Another important point of discussion at ICBC was the latest case law surrounding telemedicine and platform-based models. The rulings and ongoing proceedings show that the existing legal framework is functioning and that the market is being shaped and clarified through the courts. From the industry’s perspective, that is an important signal. Legal questions are being addressed, unlawful models are being reviewed, and the boundaries of compliant market participation are becoming clearer over time. That ultimately strengthens the argument against the need for an additional medical cannabis reform. If the legal framework continues to be refined through case law, there is good reason to believe that compliant market participants will prevail in the long run without the need for new blanket restrictions. 

Germany as a European Hub 

Against this backdrop, one broader trend is becoming increasingly clear: Germany is positioning itself as the central hub of the cannabis industry in Europe. ICBC once again underscored that development. Despite ongoing regulatory debates, Germany remains the market the industry is watching, and the one where investment, innovation and strategic partnerships are increasingly concentrated. The regulatory environment remains highly structured and demanding, but anyone following developments in Berlin can see not only the current challenges, but also the growing potential of a European market in which Germany is already playing a leading role. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,